MONOPAR THERAPEUTICS INC(NASDAQ:MNPR) stock News

MNPR Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Benzinga - Mentions: CME UNFI VRTX FCX ...

CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday

7 days ago - By: Monopar Therapeutics Inc.

Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

7 days ago - By: Monopar Therapeutics Inc.

Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

7 days ago - By: Monopar Therapeutics Inc.

Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients

7 days ago - By: Monopar Therapeutics Inc.

Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients

15 days ago - By: Investor's Business Daily

Why Monopar Therapeutics, A Top 1% Biotech Stock, Just Surged Into A Breakout

17 days ago - By: Monopar Therapeutics Inc.

Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting

a month ago - By: Monopar Therapeutics Inc.

Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting

17 days ago - By: Monopar Therapeutics Inc.

Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting

2 months ago - By: Monopar Therapeutics Inc.

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

2 months ago - By: Monopar Therapeutics Inc.

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

3 months ago - By: Benzinga - Mentions: CHH HST HLT SEPN

This Hilton Worldwide Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

4 months ago - By: Monopar Therapeutics Inc.

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

4 months ago - By: Monopar Therapeutics Inc.

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

4 months ago - By: Monopar Therapeutics Inc.

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

5 months ago - By: Monopar Therapeutics Inc.

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

5 months ago - By: Monopar Therapeutics Inc.

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

5 months ago - By: Monopar Therapeutics Inc.

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

5 months ago - By: Monopar Therapeutics Inc.

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

5 months ago - By: Yahoo Finance - Mentions: NUTX CMRX FITB MASS ...

Why Nutex Health Inc. (NUTX) is Surging in 2025

5 months ago - By: Yahoo Finance - Mentions: AGL CMRX SYY FITB ...

Why agilon health, inc. (AGL) is Surging in 2025

5 months ago - By: Yahoo Finance - Mentions: TLSA PHH ATPC AGL ...

Why Tiziana Life Sciences Ltd (TLSA) is Surging in 2025

5 months ago - By: Yahoo Finance - Mentions: PVLA TIGO SYY AGL ...

Why Monopar Therapeutics Inc. (MNPR) is Surging in 2025

5 months ago - By: Yahoo Finance - Mentions: DERM NVCT CMRX MASS

Why Journey Medical Corporation (DERM) is Surging in 2025

5 months ago - By: Monopar Therapeutics Inc.

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

5 months ago - By: Monopar Therapeutics Inc.

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

6 months ago - By: Monopar Therapeutics Inc.

Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments

6 months ago - By: Monopar Therapeutics Inc.

Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments

9 months ago - By: Monopar Therapeutics Inc.

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

9 months ago - By: Monopar Therapeutics Inc.

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

10 months ago - By: Monopar Therapeutics Inc.

Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

10 months ago - By: Monopar Therapeutics Inc.

Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

10 months ago - By: Monopar Therapeutics Inc.

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

10 months ago - By: Monopar Therapeutics Inc.

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

a year ago - By: Monopar Therapeutics Inc.

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

a year ago - By: Monopar Therapeutics Inc.

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

a year ago - By: Monopar Therapeutics Inc.

MONOPAR THERAPEUTICS INC (MNPR) Stock News

MNPR Latest News, Press Relases and Analysis

CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday

Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients

Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients

Why Monopar Therapeutics, A Top 1% Biotech Stock, Just Surged Into A Breakout

Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting

Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting

Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

This Hilton Worldwide Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

Why Nutex Health Inc. (NUTX) is Surging in 2025

Why agilon health, inc. (AGL) is Surging in 2025

Why Tiziana Life Sciences Ltd (TLSA) is Surging in 2025

Why Monopar Therapeutics Inc. (MNPR) is Surging in 2025

Why Journey Medical Corporation (DERM) is Surging in 2025

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments

Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock